Do SORT1 rs12740374 and APOB variants affect lipid metabolism and cardiovascular risk?

Genetic variations at the SORT1 and APOB loci play key roles in regulating lipid metabolism and driving cardiovascular susceptibility through distinct cellular mechanisms.

Clinical and genetic evidence

• SORT1 rs12740374 effect: Each minor (LDL-lowering) allele of the noncoding rs12740374 variant is associated with a reduction in plasma LDL cholesterol of approximately 0.13 standard deviations (equivalent to a decrease of 0.18 to 0.19 mmol/L) and a corresponding reduction in myocardial infarction risk.
• APOB variants and cardiovascular risk: The APOB Arg3500→Gln (R3500Q) missense mutation causes familial defective apoB-100, leading to severe elevations in circulating LDL-C. Conversely, protective protein-truncating variants in APOB significantly lower circulating apolipoprotein B (apoB)-containing lipoproteins, resulting in an estimated 72% reduction in coronary heart disease risk. Common variants like rs1367117 also contribute to variations in apoB concentration.

Mechanistic pathways

• Hepatic sortilin regulation: The SORT1 rs12740374 variant alters chromatin accessibility to create a CCAAT/enhancer-binding protein (C/EBP) transcription factor binding site within a hepatic enhancer, driving increased liver-specific SORT1 expression.
• Dual-action lipid clearance: Elevated hepatocyte sortilin binds apoB-100 inside the secretory pathway, directing very-low-density lipoprotein (VLDL) precursors to lysosomal degradation rather than export. Additionally, surface-expressed sortilin serves as an alternative clearance receptor that directly internalizes extracellular LDL for lysosomal catabolism.
• Apolipoprotein B receptor interaction: The APOB gene encodes the primary structural protein of LDL particles. Mutation of the LDLR-binding region (such as R3500Q) alters the conformation of apoB-100, preventing efficient LDL receptor binding, slowing cellular clearance, and driving lipid accumulation.

Bottom line

• Genetically driven increases in hepatic sortilin (SORT1 rs12740374) and variations in APOB structure and expression directly dictate the secretion, receptor binding, and clearance of apoB-containing lipoproteins, acting as primary causal determinants of lifelong cardiovascular risk.